SCHEMBL986554

SCHEMBL986554

CC1(c2ccc3[nH]ccc3c2)CC(=O)N(Cc2ccccc2)C1=O

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SLC6A2 P23975 8/20 0.47
SLC6A4 P31645 8/20 0.47
SLC6A3 Q01959 8/20 0.47
CYP2D6 P10635 7/20 0.47
KCNH2 Q12809 1/20 0.47
MAPK14 Q16539 2/20 0.43
ELANE P08246 1/20 0.41
PTGDR2 Q9Y5Y4 1/20 0.40
CYP19A1 P11511 1/20 0.40
GRM2 Q14416 1/20 0.40
ACHE P22303 1/20 0.39
HTR4 Q13639 1/20 0.39
SIGMAR1 Q99720 1/20 0.39
EPHX1 P07099 1/20 0.38
EPHX2 P34913 1/20 0.38
TRPA1 O75762 1/20 0.38
KDM1A O60341 1/20 0.38
MAOA P21397 1/20 0.38
MAOB P27338 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL984732 0.83 SLC6A2 (0.48) SLC6A2SLC6A4SLC6A3CYP2D6KCNH2
SCHEMBL984625 0.82 SLC6A2 (0.51) SLC6A2SLC6A4SLC6A3CYP2D6KCNH2
SCHEMBL24126788 0.79 ELANE (0.56) ELANEPTGDR2GRM2
SCHEMBL984052 0.79 SLC6A2 (0.47) SLC6A2SLC6A4SLC6A3CYP2D6KCNH2
SCHEMBL980979 0.79 CTNNB1 (0.45) SLC6A2SLC6A4SLC6A3CYP2D6KCNH2
SCHEMBL985058 0.78 SLC6A2 (0.53) SLC6A2SLC6A4SLC6A3CYP2D6KCNH2
SCHEMBL983263 0.77 SLC6A2 (0.50) SLC6A2SLC6A4SLC6A3CYP2D6KCNH2
SCHEMBL1990761 0.76 CYP19A1 (0.57) ELANEPTGDR2CYP19A1GRM2
SCHEMBL1990759 0.76 CYP19A1 (0.57) ELANEPTGDR2CYP19A1GRM2
SCHEMBL983277 0.76 SLC6A2 (0.47) SLC6A2SLC6A4SLC6A3CYP2D6KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2257545-B1 PYRROLIDINYL DERIVATIVES AND USES THEREOF HOFFMANN LA ROCHE (CH) 2011-08-31 EP disclosed
US-20110021556-A1 PYRROLIDINYL DERIVATIVES AND USES THEREOF HOFFMAN-LA ROCHE, INC. (US) 2011-01-27 US disclosed
EP-2257545-A1 PYRROLIDINYL DERIVATIVES AND USES THEREOF F. Hoffmann-La Roche AG (CH) 2010-12-08 EP disclosed
WO-2009115427-A1 PYRROLIDINYL DERIVATIVES AND USES THEREOF F. HOFFMANN-LA ROCHE AG (CH) 2009-09-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110021556-A1 PYRROLIDINYL DERIVATIVES AND USES THEREOF SLC6A3, MAOB, TPH2 SLC6A2 6/4885SLC6A4 8/4885SLC6A3 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.